20.07.2017 • NewsElaine BurridgefiberTeijin

Teijin Aramid Expands Dutch Fiber Capacity

(c) TEIJIN ARAMID
(c) TEIJIN ARAMID

Increasing demand for its Twaron high-performance aramid fiber has prompted Teijin Aramid to invest in new spinning technology that will boost capacity at its plant in Emmen, the Netherlands. The new capacity is due to start up in the first quarter of 2019. Capacity details and investment costs were not revealed.

The company said Twaron is being used more often and in more advanced products in different industries. “This investment underscores our ambition to produce and deliver sustainable and cost-efficient products to the market and reinforces our position as global market leader,” said CEO and president, Gert Frederiks. “It will enable us to meet the growing market demand and simultaneously implement the latest technology.”

Teijin said the new technology, which will further automate its spinning process, will bring a huge improvement in the amount of physical work for operators and is in line with its plans to continue automating and improving the health, safety and environment (HSE) aspects of its operations.

As of Apr. 1, Teijin merged all its aramid activities into one global business unit, Teijin Aramid is now responsible for all aramid and PE products. As well as the Netherlands, Teijin Aramid also produces the high-performance fibers in Thailand and Japan.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.